Isavuconazole for the Treatment of Aspergillosis and Mucormycosis in the Brazilian Private Healthcare System

Authors

  • Marcos Santos Sociedade Brasileira de Auditoria Médica, Presidente
  • Jaime Rocha Médico clínico e infectologista. Professor de medicina da PUC-PR
  • Emerson Gatti Onco-Hematologista. Médico responsável Técnico pelo serviço verticalizado de Onco Hematologia da Unimed de Campinas
  • Bruno Marques Knigth Therapeutics Brasil
  • Lívia Maria Gonçalves Barbosa Knigth Therapeutics Brasil
  • Rodrigo Dodt Knigth Therapeutics Brasil

DOI:

https://doi.org/10.66305/jbas.v5i2.28

Keywords:

Isavuconazole, Mucormycosis, Aspergillosis

Abstract

The text analyzes the use of isavuconazole in the treatment of invasive fungal infections within the Brazilian private healthcare system. It begins by highlighting that these infections are associated with high mortality among immunocompromised patients and that the choice of antifungal therapy should consider efficacy, safety, drug interactions, pharmacokinetics, and the availability of both intravenous and oral formulations.

     

Downloads

Published

2025-09-30

How to Cite

Santos, M., Rocha, J., Gatti, E., Marques, B., Maria Gonçalves Barbosa, L., & Dodt, R. (2025). Isavuconazole for the Treatment of Aspergillosis and Mucormycosis in the Brazilian Private Healthcare System. Brazilian Journal of Health Auditing, 5(2), 9–24. https://doi.org/10.66305/jbas.v5i2.28

Issue

Vol. 5 No. 2 (2025): Jornal Brasileiro de Auditoria em Saúde

Section

Original articles

License

Copyright (c) 2026 Marcos Santos, Jaime Rocha, Emerson Gatti, Bruno Marques, Lívia Maria Gonçalves Barbosa, Rodrigo Dodt

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The articles published do not necessarily express the opinion of the journal and are the sole responsibility of the authors.